Newsletter #2 – 2025
In this issue:
Bayer v Sandoz, STADA, Teva, Glenmark, and Viatris over rivaroxaban products
STADA and Sandoz v Takeda over the validity of lisdexamfetamine SPC and lisdexamfetamine product
Newsletter #2 – 2025 Read More »
Glenmark
Newsletter #1 – 2025
In this issue:
Bayer v Sandoz, STADA, Teva, Glenmark, and Viatris over rivaroxaban products
STADA and Sandoz v Takeda over the validity of lisdexamfetamine SPC and lisdexamfetamine product
Newsletter #1 – 2025 Read More »